You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

35 search results for: barrier dysfunction

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children
expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

Dermatology
Dr. Stephan Weidinger describes the roles of IL-4 and IL-13 in skin barrier dysfunction, and the potential of early control of type 2 inflammation to modify disease course. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.
View more
Skin Dysbiosis in AD
expert video

Skin Dysbiosis in AD

Dermatology
Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.
View more
Skin <b>Barrier</b>, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.
View more
Targeting Type 2 Inflammation: ​Skin <b>Barrier</b> Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
Role of Type 2 Inflammation in Skin <b>Barrier</b> Disruption and Itch
expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
View more
Connecting the Dots from Type 2 Inflammation to Patient Perspectives
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Type 2 Inflammation
Learn the connection between chronic type 2 inflammation, symptoms, and impact on quality of life in diseases with underlying type 2 inflammation
View more
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Pulmonology
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
View more
The Cycle of Inflammation in Adult Asthma
interactivity

The Cycle of Inflammation in Adult Asthma

Pulmonology
Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients
View more
Role of Type 2 Inflammation Across Different Chronic Diseases
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Type 2 Inflammation
Profs. Oscar Palomares, Stephan Weidinger, Valerie Lund, and Ulrike von Arnim highlight how underlying type 2 inflammation contributes to key symptoms of inflammatory diseases across organs
View more
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Dermatology
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region